Cargando…
Intralenticular Ozurdex® - One Year Later
Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despi...
Autores principales: | Regan, Kathleen A., Blake, Charles R., Lukowski, Zachary L., Iyer, Siva S.R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836234/ https://www.ncbi.nlm.nih.gov/pubmed/29515431 http://dx.doi.org/10.1159/000485318 |
Ejemplares similares
-
Inadvertent intralenticular Ozurdex removal
por: Roy, Madhurima, et al.
Publicado: (2022) -
Intralenticular Ozurdex injection in an eye with thicker lens and the therapeutic effect maintained for 15 months
por: Li, Mu, et al.
Publicado: (2022) -
Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens
por: Albuainain, Abdulrahman, et al.
Publicado: (2020) -
Immortal Ozurdex: A 10-month follow-up of an intralenticular implant
por: Poornachandra, B, et al.
Publicado: (2017) -
Accidental Intralenticular Injection of Ozurdex® for Branch Retinal Vein Occlusion: Intact Posterior Capsule and Resolution of Macular Edema
por: Kurt, Ali, et al.
Publicado: (2019)